

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI XDC CAYMAN INC.

藥明合聯生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2268)

**(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON JUNE 27, 2025;
(2) CHANGE OF DIRECTORS; AND
(3) CHANGE IN COMPOSITION OF BOARD COMMITTEES**

The Board announces that

- (1) at the AGM held on June 27, 2025, all proposed resolutions as set out in the notice of the AGM were duly passed by the Shareholders by way of poll;
- (2) Dr. Weichang Zhou retired as a non-executive Director and a member of each of the Strategy Committee and the ESG Committee with effect from the conclusion of the AGM;
- (3) Dr. Jijie Gu was appointed as a non-executive Director and a member of each of the Strategy Committee and the ESG Committee with effect from the conclusion of the AGM; and
- (4) Each of Ms. Ming Shi and Mr. Kenneth Walton Hitchner III was appointed as a member of the Nomination Committee with effect from June 27, 2025.

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 27, 2025

The board (the “**Board**”) of directors (the “**Directors**”) of WuXi XDC Cayman Inc. 藥明合聯生物技術有限公司* (the “**Company**”) announces that at the annual general meeting of the Company (the “**AGM**”) held on June 27, 2025, all proposed resolutions as set out in the notice of the AGM were duly passed by the shareholders of the Company (the “**Shareholder(s)**”) by way of poll. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the circular dated May 27, 2025 (the “**Circular**”). The executive Directors, Dr. Jincai Li, Mr. Jerry Jingwei Zhang and Mr. Xiaojie Xi; the non-executive Director Dr. Zhisheng Chen; and the independent non-executive Director, Mr. Hao Zhou attended the AGM either in person or by electronic means.

The poll results taken at the AGM were as follows:

ORDINARY RESOLUTIONS		Number of Votes (Approximate%)	
		For	Against
1.	To receive the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and of the independent auditor of the Company for the year ended December 31, 2024.	962,402,690 100.000000%	0 0.000000%
2.	(a) To re-elect Dr. Zhisheng Chen as non-executive director.	945,329,757 98.23%	17,072,933 1.77%
	(b) To re-elect Mr. Kenneth Walton Hitchner III as independent non-executive director.	960,326,943 99.78%	2,075,747 0.22%
	(c) To re-elect Mr. Hao Zhou as independent non-executive director.	960,326,943 99.78%	2,075,747 0.22%
	(d) To appoint Dr. Jijie Gu as non-executive director.	959,320,224 99.68%	3,082,466 0.32%
3.	To authorise the board of directors or any duly authorized board committee to fix the directors’ remuneration for the year ending December 31, 2025.	961,515,222 99.91%	887,468 0.09%
4.	To re-appoint Messrs. Deloitte Touche Tohmatsu as auditors and to authorize the board of directors or any duly authorized board committee to fix their remuneration.	961,225,190 99.88%	1,177,500 0.12%
5.	To grant a general mandate to the directors to issue, allot and deal with the shares of the Company (excluding any treasury shares).	932,535,916 96.90%	29,866,774 3.10%
6.	To grant a general mandate to the directors to repurchase the shares of the Company (excluding any treasury shares).	962,402,690 100%	0 0%
7.	To extend the general mandate granted to the directors to issue the shares of the Company by adding thereto the shares to be repurchased by the Company.	933,959,932 97.04%	28,442,758 2.96%

As at the date of the AGM, the total number of shares of the Company in issue was 1,203,021,592 Shares, being the total number of Shares entitling the holders thereof to attend and vote on all the resolutions proposed at the AGM. The Company did not hold any treasury Shares or repurchased Shares pending cancellation.

There were no Shares entitling the holders thereof to attend and abstain from voting in favour of any resolution at the AGM as set out in Rule 13.40 of the Listing Rules.

No Shareholder has stated his/her/its intention in the Company's Circular to vote against or to abstain from voting on any of the resolutions at the AGM. As at the date of the AGM, Futu Trustee Limited, being the trustee (the "**Trustee**") holding unvested Restricted Shares granted under the Company's 2024 Share Scheme, held no Shares. Save for the Trustee who was required under Rule 17.05A of the Listing Rules to abstain from voting on matters that require Shareholders' approval under the Listing Rules, no other Shareholder was required to abstain from voting in respect of any resolution at the AGM.

The Company's Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the vote-taking at the AGM.

CHANGE OF DIRECTORS

Dr. Weichang Zhou retired as a non-executive Director and a member of each of the Strategy Committee and the ESG Committee with effect from the conclusion of the AGM to devote more time to his own personal commitments. Dr. Zhou has confirmed that he has no disagreement with the Board, and there are no matters relating to his retirement that need to be brought to the attention of the Shareholders or the Stock Exchange. The Board would like to express its sincere gratitude to Dr. Zhou for his valuable contribution to the Company during his tenure of service.

The Board is also pleased to announce that Dr. Jijie Gu has been appointed as a non-executive Director with effect from the conclusion of the AGM. The biographical details of Dr. Gu are as follows:

Dr. Jijie Gu (顧繼傑), aged 59, has been serving as President of Global Biologics Research and Chief Scientific Officer of WuXi Biologics since March 2019. Dr. Gu brings more than 20 years of drug research and development expertise and extensive management experience to the Company. He has significant expertise in target discovery, therapeutic design, protein engineering, preclinical drug discovery and early clinical development.

Previously, Dr. Gu served as a function head at AbbVie Cambridge Research Center from August 2016 to March 2019, where he led target validation and lead discovery in AbbVie Immunology for both small and large molecule drugs. Before that, he was a function head of Oncology Biologics in Global Biologics at AbbVie Bioresearch Center from April 2012 to August 2016. While at Abbott/AbbVie, Dr. Gu made critical contributions to building antibody platform technologies. He led the construction of novel biologics platform technologies, including Fc engineering, ADC technology, TCR technology, bispecific and multispecific antibody technologies and T cell engagers. He also led projects in multiple therapeutic areas relating to oncology, immunology, immuno-oncology, metabolic disease, neuroscience and ophthalmology, and contributed broadly to AbbVie Biologics portfolio and delivered several New Biological Entities (NBEs) into clinical development. Throughout his

extensive career, Dr. Gu has co-invented more than 20 filed and issued U.S. patents and has coauthored 40 publications. He currently serves on the editorial boards of the peer-reviewed journals Antibody Therapeutics.

Dr. Gu obtained his Ph.D. in Molecular Biology and Biochemistry from Peking Union Medical School in July 1996. He received postdoctoral training in Tumor Immunology at the Dana Farber Cancer Institute in August 1999, a principal teaching affiliate of Harvard Medical School and in Cancer Cell Biology at the Harvard School of Public Health in February 2002.

Dr. Gu does not, at present, nor did he in the past three years, hold any directorship in any other public companies the securities of which are listed in Hong Kong or overseas.

Dr. Gu has entered into a director's appointment letter with the Company for a term of three years which is terminable by either party with one month's written notice, and he is subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the provisions of the articles of association of the Company. Dr. Gu is not entitled to any remuneration for his services as a non-executive Director.

As at the date of this announcement, Dr. Gu did not have any interests in the Shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above and except for acting as the President of Global Biologics Research and the Chief Scientific Officer of WuXi Biologics and being interested in 4,445 shares of WuXi Biologics, 2,347,916 restricted shares of WuXi Biologics granted to him under its restricted share award scheme and 588,222 restricted shares of WuXi Biologics granted to him under its global partner program share scheme. As of the date of this announcement, Dr. Gu does not have any relationships with any Directors or senior management or substantial Shareholders or controlling shareholders of the Company.

There is no information which is discloseable nor is/was Dr. Gu involved in any of the matters required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to Dr. Gu's election that need to be brought to the attention of the Shareholders.

The Board would like to extend its warmest welcome to Dr. Gu on his new appointment.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

Dr. Weichang Zhou retired as a non-executive Director and a member of each of the Strategy Committee and the ESG Committee with effect from the conclusion of the AGM on June 27, 2025. The Board further announces that Dr. Jijie Gu was appointed as a member of each of the Strategy Committee and the ESG Committee and each of Ms. Ming Shi and Mr. Kenneth Walton Hitchner III was appointed as a member of the Nomination Committee, all with effect from June 27, 2025.

By order of the Board
WuXi XDC Cayman Inc.
Dr. Jincal LI

Executive Director and Chief Executive Officer

Hong Kong, June 27, 2025

As at the date of this announcement, the board of directors of the Company comprises (i) Dr. Jincal LI, Mr. Jerry Jingwei ZHANG and Mr. Xiaojie XI as executive directors; (ii) Dr. Zhisheng CHEN, Ms. Ming SHI and Dr. Jijie GU as non-executive directors; and (iii) Dr. Ulf GRAWUNDER, Mr. Kenneth Walton HITCHNER III and Mr. Hao ZHOU as independent non-executive directors.

* *For identification purpose only*